Bedrijfsoverzicht
Guardian Pharmacy Services, Inc. operates as a pharmacy service company dedicated to providing a suite of technology-enabled services to residents within long-term health care facilities (LTCFs) across the United States. The company leverages its individualized clinical, drug dispensing, and administration capabilities to support the operational needs of these essential healthcare environments. Operating within the Healthcare sector and specifically the Medical Care Facilities industry, the firm focuses on the specialized distribution and management of pharmaceuticals for institutional settings. This enterprise commands a substantial market capitalization of $2.52B, reflecting a significant valuation within the healthcare infrastructure landscape. The company reported annual revenue of $1.45B, which places it among the larger players in its niche, supported by a workforce of 3600 employees. These financial metrics indicate a company of considerable scale that has established a dominant presence in the specialized pharmacy services market, utilizing its extensive reach to serve a broad network of LTCFs.
Financiële gezondheid
The company reported revenue of $1.45B over the trailing twelve months, generating a net income of $49.22M and an EBITDA of $102.62M during the same period. The significant disparity between the revenue figure and the net income reveals a cost structure where operating expenses and taxes consume a substantial portion of top-line growth, resulting in a net income that is roughly one-third of the EBITDA. Free cash flow stands at $73.88M, which provides the organization with meaningful financial flexibility to fund operations, maintain its technology infrastructure, or pursue strategic acquisitions without immediate reliance on external financing. The gross margin is recorded at 20.2%, indicating that the company retains a fifth of its revenue after covering the direct costs associated with dispensing medications. The operating margin sits at 8.9%, suggesting that after covering all operating expenses, the firm retains slightly less than ten percent of revenue as operational profit, a typical range for service-oriented healthcare businesses. The profit margin is 3.4%, which reflects the final profitability after all expenses, interest, and taxes are accounted for. On the balance sheet, cash holdings of $65.62M exceed total debt of $44.72M, indicating a conservative liquidity position, further supported by a debt-to-equity ratio of 20.52%. The current ratio of 1.38 demonstrates that the company possesses sufficient short-term assets to cover its short-term liabilities, ensuring stable short-term liquidity. Additionally, the return on equity is 26.6% and the return on assets is 13.7%, metrics that collectively reveal highly effective management in generating returns relative to the capital invested and the total asset base employed.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 50.19, while the forward P/E ratio is 28.91. The substantial difference between these two metrics implies that the market expects a significant increase in earnings in the coming years, as the forward multiple is considerably lower than the historical average. The price-to-book ratio stands at 12.05, which indicates that the market values the company at a premium of over twelve times its net asset book value, suggesting high investor confidence in intangible assets or future growth potential. Alternative valuation metrics such as the price-to-sales ratio of 1.74 and the EV/EBITDA of 24.07 offer additional context on the stock's pricing relative to its sales volume and operational earnings power. Regarding trading ranges, the 52-week high is $41.36 and the 52-week low is $19.17, establishing a wide price corridor where the current share price fluctuates. The beta value is listed as N/A, meaning volatility data relative to the broader market is not currently available for this specific security. These valuation figures must be interpreted collectively, as a high P/E and a low P/S ratio can coexist if sales growth is anticipated to be explosive or if the P/S metric captures revenue from non-recurring events.
Growth & Income
Revenue growth year-over-year is 17.4%, demonstrating a robust expansion in top-line sales, while earnings growth year-over-year is listed as N/A due to insufficient data points to calculate a precise percentage change in the provided facts. Although exact earnings growth rates are not quantified in the available data, the company's substantial free cash flow suggests it generates significant cash relative to its net income, allowing for reinvestment strategies. As a non-dividend payer, the company maintains a dividend yield of 0.0% and a payout ratio of 0.0%, indicating that it does not distribute profits to shareholders but instead reinvests earnings into business growth, technology upgrades, or debt reduction. The absence of a dividend policy aligns with the company's strategy to prioritize capital retention and expansion within the long-term care pharmacy sector. Overall, the growth and income profile is characterized by strong revenue expansion and a zero-dividend approach, positioning the firm for capital appreciation rather than current income generation for investors.